Neuroplay

NeuroPlay operates at the intersection of digital health, medical devices, neuroscience, and cognitive training. Its differentiation is the combination of EEG-based neurofeedback, a wireless wearable form factor, and tablet-delivered cognitive exercises aimed at two specific populations: older adults experiencing age-related cognitive decline and people recovering after stroke. The product is positioned for use at home or in clinical settings, potentially reducing dependence on continuous specialist supervision. That limits direct assessment of relative pricing, regulatory maturity, distribution, and clinical evidence. With an estimated workforce of one to ten employees and no disclosed funding, the company appears to be an early-stage specialist rather than a scaled platform. Its market position currently rests more on focused use cases and integrated hardware-software delivery than on demonstrated commercial scale.

NeuroPlay's trajectory appears to have progressed from company formation in 2018 toward development and evaluation of a focused EEG-biofeedback product. Radoslaw Tracz has been identified as a co-founder since October 2018, while the company remains classified as active with an estimated workforce of one to ten employees. The main product inflection point is the integration of a wireless EEG headband with a tablet application and interactive cognitive-training software. The product targets both senior cognitive support and post-stroke rehabilitation, giving NeuroPlay two adjacent care markets but also requiring validation across distinct clinical needs. Consequently, there is insufficient evidence to claim rapid headcount, revenue, or geographic growth. The current trajectory is best characterized as early-stage product development with patient-use validation and limited visibility into commercialization.